key: cord-0733979-n4sjajbo authors: Ye, Zheng; Song, Bin title: COVID-19 related liver injury: call for international consensus date: 2020-05-17 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2020.05.013 sha: 1542a9f6bbda22c92482a9e8c9c9c701cfb4fa7d doc_id: 733979 cord_uid: n4sjajbo nan To the Editor: We read with interest the article by Fan et al. regarding the clinical characteristics of COVID-19 patients with liver damage 1 . The authors defined abnormal liver damage in their study, and found patients with liver function abnormality was associated with longer hospital stay and may might have been related to use of lopinavir/ritonavir used during hospitalization. This study is interesting and provides the direction for future researches, however, there is a need to address the importance of standardized definition of COVID-19 related liver injury, which is currently unavailable; it also , and calls for an international consensus in this regard. Liver function abnormalities abnormalitiy was frequent, but usually mild, in COVID-19 patients. As previously reported, the abnormal liver function inIn patients with COVID-19, abnormal liver function may be resulted from direct viral damage, immune-mediated inflammation, drug hepatotoxicity, hypoxia-reperfusion dysfunction or reactivation of pre-existing liver diseases 2 . It is worthwhile to explore the mechanisms and clinical outcomes of liver dysfunction for better understanding and treatment of COVID-19. However, as a new contagious disease, there is no consensus on the definition of COVID-19 associated liver injury at present, and its definition varies in recent studies (Table 1) . Firstly, the parameters for evaluating liver function were different among studies, although alanine aminotransferase (ALT), aspartate transaminase (AST) and total bilirubin (TBIL) were mostly included 3, 4, 5 . Several studies also included alkaline phosphatase (ALP) and gamma glutamyl-transpeptidase (GGT) for the assessment of liver function 6,7 , probably because the angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, was reported to be highly expressed in cholangiocytes 8 . Interestingly, current study included lactate dehydrogenase (LDH) as a parameter for liver damage in COVID-19 patients 1 , which was normally regarded as an indicator for heart, kidney and liver dysfunction, and thus may be less specific in this regard. The difference on diagnostic parameters may affect the grouping of liver injury and non-liver injury, and thus compromise the results. More importantly, due to the different criteria on the level of elevated liver enzymes, researchers and clinicians may overestimate the value of abnormal liver function both in scientific aspect and clinical practice. Several studies reported the potential clinical outcome of COVID-19 patients with liver injury, including longer hospitalization 1 , severe pulmonary lesions 5 and higher odds of developing severe pneumonia 9 . In 4 contrast, Zhang et al. 7 reported that although the impairment of liver function did exist in COVID-19, it was not a prominent feature and may not have serious clinical consequences. Notably, in these studies, some researchers defined liver injury as any liver function parameter test above the upper limit of normal (ULN) 1,5 , however, others defined it as liver enzymes higher than two or three times of ULN 9 , or according to the guideline of drug-induced liver injury 7 , which may be the reason for the controversial mixed results. Together with the comment published by Bangash et al. 10 , we think it may be inappropriate to consider the mild elevation and fluctuation of liver enzymes (i.e. just slightly above the ULN) as the clinically significant liver injury, which may be predominantly a clinical distraction. Furthermore, the diagnostic time point (i.e. on admission or during disease progression) of liver injury 1, 11 , and the standardized definition of liver injury patterns 6,9 ( i.e. hepatocellular type, cholangiocytes type and mixed type) in COVID-19 also varies and remains open questions. Overall, from a scientific point of view, the lack of standardization in the definition is undoubtedly an important issue, as it may jeopardize the generalizability of the conclusions from those these studies. Although liver function abnormalities and clinically significant liver injury in 5 COVID-19 should be further investigated, we suggest researchers pay extreme attention to the terminology and its definition , to avoid ambiguity in future analysis, and overtreatment in clinical practice. Clinical Features of COVID-19-Related Liver Damage COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies Liver injury during highly pathogenic human coronavirus infections Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study Implication of nonalcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection Characteristics of Liver Tests in COVID-19 Patients COVID-19 and the liver: little cause for concern COVID-19 and liver disease Liver injury is common in non-ICU hospitalized COVID-19 patients and may relate to severe pulmonary imaging lesions.Zhang et al [7] Original article -Abnormal Liver function: initial test above ULN, including ALT, ASL, TBIL, ALP, GGT and ALB. -Liver injury: according to the criteria of iSAEC. Sun et al [11] Comment COVID-19 associated liver injury is defined as any liver damage occurring during disease progression and treatment of COVID-19 in patients with or without pre-existing liver diseases.Xu et al [3] Review Liver injury was mainly indicated by abnormal ALT/AST levels accompanied by slightly elevated bilirubin levels.ALT, alanine aminotransferase; AST, aspartate transaminase; TBIL, total bilirubin; ALP, alkaline phosphatase; GGT, gamma glutamyl-transpeptidase; LDH, lactate dehydrogenase; ULN, upper limit of normal; NAFLD, nonalcoholic fatty liver disease; ALD, alcoholic liver disease; CLD, chronic liver disease; ICU; iSAEC, international Serious Adverse Event Consortium; NA, not applicable.